Pharmaceutical composition for the treatment of bone fracture

Details Pharmaceutical composition for the treatment of bone fracture Pharmaceutical composition for the treatment of bone fracture

2011-04-12

2011-04-12

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07923443

ABSTRACT:
Disclosed herein is a composition for the treatment bone fracture comprising N-hydroxy-4-{5-[4-( 5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxyl-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts thereof as a medicinally effective ingredient. The composition of the present invention can significantly reduce the volume of bony callus, and increase bony density and strength of bony callus, and decrease the contents of connective tissue and cartilage tissue in bony callus, and thus promote loss and ossification of the bony callus formed during the fracture healing process. Therefore, the composition of the present invention is useful for the treatment of bone fracture.

REFERENCES:
patent: 2002/0037279 (2002-03-01), Vandenburgh
patent: WO98/33779 (1998-08-01), None
patent: WO 03007947 (2003-01-01), None
Cebesoy, Oguz, et al.; “Effect of strontium ranelate on fracture healing in rat tibia”; Joint Bone Spine, vol. 74 (2007), pp. 590-593, 2007 Elsevier Masson SAS.
Li, Jiliang, et al.; “Effect of Bisphosphonate (Incadronate) on Fracture Healing of Long Bones in Rats”; Journal of Bone and Mineral Research, vol. 14, No. 6 (1999), pp. 969-979, Blackwell Science, Inc., 1999 American Society for Bone and Mineral Research.
Fleisch, Herbert; “Can Bisphosphonates Be Given to Patients with Fractures?”; Journal of Bone and Mineral Research, vol. 16, No. 3 (2001), pp. 437-440, 2001 American Society for Bone and Mineral Research.
Kinoshita, T., et al.; “Phosphodiesterase Inhibitors, Pentoxifylline and Rolipram, Increase Bone Mass Mainly by Promoting Bone Formation in Normal Mice”; Bone, vol. 27, No. 6, pp. 811-817, Dec. 2000, 2000 Elsevier Science Inc.
Wang Elizabeth A., et al.; “Recombinant human bone morphogenetic protein induces bone formation”; Proc. Natl. Acad. Sci. USA, vol. 87, pp. 2220-2224, Mar. 1990.
Kawamura, Morio, M.D., et al.; “Induction of Callus Formation by Implants of Bone Morphogenetic Protein and Associated Bone Matrix Noncollagenous Proteins”; Clinical Orthopaedics & Related Research, vol. 236, pp. 240-248, Nov. 1998.
Li, Chaoyang, et al.; “Long-Term Effect of Incadronate Disodium (YM-175) on Fracture Healing of Femoral Shaft in Growing Rats”; Journal of Bone and Mineral Research, vol. 16, No. 3, pp. 429-436, 2001, 2001 American Society for Bone and Mineral Research.
Traumatol, Chin J. et al.; “Early period of fracture healing in ovariectomized rats”; Abstract (1 pg.); PubMed (www.pubmed.gov), vol. 6, No. 3, pp. 160-166, Jun. 2003, PMID: 12749788 [PUBMED—indexed for MEDLINE].
Lee, Sung-Eun, “Design, Syntheses, and Evaluation of Functional Molecules for the Treatment of LTB4 Related Disease and Electroluminescent Device”; Aug. 1999.

Affiliated with

Also associated with

Rating

Pharmaceutical composition for the treatment of bone fracture does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition for the treatment of bone fracture, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the treatment of bone fracture will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2625066